DE3583900D1 - Adrenergische verbindungen. - Google Patents

Adrenergische verbindungen.

Info

Publication number
DE3583900D1
DE3583900D1 DE8585106209T DE3583900T DE3583900D1 DE 3583900 D1 DE3583900 D1 DE 3583900D1 DE 8585106209 T DE8585106209 T DE 8585106209T DE 3583900 T DE3583900 T DE 3583900T DE 3583900 D1 DE3583900 D1 DE 3583900D1
Authority
DE
Germany
Prior art keywords
adrenergic
connections
adrenergic connections
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE8585106209T
Other languages
English (en)
Inventor
John Francis Debernardis
Fatima Zehra Basha
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abbott Laboratories
Original Assignee
Abbott Laboratories
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Laboratories filed Critical Abbott Laboratories
Application granted granted Critical
Publication of DE3583900D1 publication Critical patent/DE3583900D1/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/06—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/20—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D233/22—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/26—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
DE8585106209T 1984-06-06 1985-05-21 Adrenergische verbindungen. Expired - Fee Related DE3583900D1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US61777084A 1984-06-06 1984-06-06

Publications (1)

Publication Number Publication Date
DE3583900D1 true DE3583900D1 (de) 1991-10-02

Family

ID=24474996

Family Applications (1)

Application Number Title Priority Date Filing Date
DE8585106209T Expired - Fee Related DE3583900D1 (de) 1984-06-06 1985-05-21 Adrenergische verbindungen.

Country Status (4)

Country Link
EP (1) EP0166937B1 (de)
JP (1) JPH0635444B2 (de)
CA (1) CA1259995A (de)
DE (1) DE3583900D1 (de)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6908910B2 (en) 1993-08-06 2005-06-21 The Children's Medical Center Corporation Estrogenic compounds as anti-mitotic agents
US5504074A (en) 1993-08-06 1996-04-02 Children's Medical Center Corporation Estrogenic compounds as anti-angiogenic agents
US7091181B2 (en) 1994-12-12 2006-08-15 Omeros Corporation Method of inhibition of pain and inflammation during surgery comprising administration of soluble TNF receptors
US7973068B2 (en) 1998-10-20 2011-07-05 Omeros Corporation Arthroscopic irrigation solution and method for peripheral vasoconstriction and inhibition of pain and inflammation
US20030087962A1 (en) 1998-10-20 2003-05-08 Omeros Corporation Arthroscopic irrigation solution and method for peripheral vasoconstriction and inhibition of pain and inflammation
DE69924536T2 (de) * 1998-10-20 2006-02-16 Omeros Corp., Seattle Spülende lösung und methoden zur hemmung von schmerzen und entzündungen
FR2787451B1 (fr) * 1998-12-18 2001-01-26 Adir Nouveaux composes imidazoliniques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US7087592B1 (en) 1999-08-23 2006-08-08 Entre Med, Inc. Compositions comprising purified 2-methoxyestradiol and methods of producing same
US7135581B2 (en) 2000-08-18 2006-11-14 Entremed, Inc. Antiangiogenic agents
AU2003209439A1 (en) * 2002-01-30 2003-09-02 Entremed, Inc. Non-steroidal analogs of 2-methoxyestradiol
JP4527379B2 (ja) * 2003-10-17 2010-08-18 田辺三菱製薬株式会社 ５−ベンジルオキシ−１，２，３，４−テトラヒドロナフタレン誘導体、及びその製造法
WO2005089256A2 (en) 2004-03-12 2005-09-29 Entremed, Inc. Antiangiogenic agents
RU2440344C2 (ru) * 2006-01-27 2012-01-20 Ф.Хоффманн-Ля Рош Аг Применение 2-имидазолов для лечения расстройств цнс
JP2009530388A (ja) 2006-03-20 2009-08-27 エントレメッド インコーポレイテッド ２−メトキシエストラジオールの疾患修飾性抗関節炎活性
BRPI0717939A2 (pt) 2006-10-19 2013-12-03 Hoffmann La Roche Aminometil-4-imidazóis
CN101535292A (zh) 2006-11-02 2009-09-16 弗·哈夫曼-拉罗切有限公司 作为痕量胺相关受体的调节剂的取代的2-咪唑类化合物
JP2010510184A (ja) 2006-11-16 2010-04-02 エフ．ホフマン−ラ ロシュ アーゲー 置換４−イミダゾール類
BRPI0720047A2 (pt) 2006-12-13 2013-12-24 Hoffmann La Roche 2-imidazóis como ligantes para receptores associados a aminas de traço (taar)
US20080146523A1 (en) 2006-12-18 2008-06-19 Guido Galley Imidazole derivatives
KR101174191B1 (ko) 2007-02-02 2012-08-14 에프. 호프만-라 로슈 아게 중추 신경계 장애의 치료용 ｔａａｒ1 리간드로서 2-아미노옥사졸린
WO2008098857A1 (en) 2007-02-15 2008-08-21 F. Hoffmann-La Roche Ag 2-aminooxazolines as taar1 ligands
KR101150561B1 (ko) 2007-07-02 2012-06-08 에프. 호프만-라 로슈 아게 미량 아민 결합 수용체(ｔａａｒ)에 대한 양호한 친화도를 갖는 2-이미다졸린
KR101150628B1 (ko) 2007-07-03 2012-05-31 에프. 호프만-라 로슈 아게 4-이미다졸린 및 항우울제로서 이의 용도
KR101133862B1 (ko) 2007-07-27 2012-04-06 에프. 호프만-라 로슈 아게 Ｔａａｒ 리간드로서의 2-아제티딘메테인아민 및 2-피롤리딘메테인아민
EP2185502A1 (de) 2007-08-03 2010-05-19 F. Hoffmann-Roche AG Pyridincarboxamid- und benzamidderivate als taar1-liganden
US8242153B2 (en) 2008-07-24 2012-08-14 Hoffmann-La Roche Inc. 4,5-dihydro-oxazol-2YL derivatives
US8354441B2 (en) 2009-11-11 2013-01-15 Hoffmann-La Roche Inc. Oxazoline derivatives
US9452980B2 (en) 2009-12-22 2016-09-27 Hoffmann-La Roche Inc. Substituted benzamides
AR090557A1 (es) * 2012-04-02 2014-11-19 Orion Corp DERIVADOS IMIDAZOLICOS AGONISTAS ADRENERGICOS a2
SG10201913878YA (en) 2016-03-17 2020-03-30 Hoffmann La Roche 5-ethyl-4-methyl-pyrazole-3-carboxamide derivative having activity as agonist of taar

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2948724A (en) * 1958-04-21 1960-08-09 Sahyun Halogenated derivatives of tetrahydro-1-naphthyl cyclic amidines
NL7310741A (nl) * 1973-08-03 1975-02-05 Akzo Nv Nieuwe n-hydroxy-amidine verbindingen.
FR2539415B1 (fr) * 1983-01-14 1985-09-13 Adir Derives de la d-2 imidazoline, leur preparation et leur application en therapeutique
FR2542738A1 (fr) * 1983-03-18 1984-09-21 Synthelabo Indanyl-2 d2-imidazoline, procede pour la preparer, et compositions pharmaceutiques qui la contiennent

Also Published As

Publication number Publication date
EP0166937A2 (de) 1986-01-08
EP0166937A3 (en) 1986-01-22
EP0166937B1 (de) 1991-08-28
JPH0635444B2 (ja) 1994-05-11
CA1259995A (en) 1989-09-26
JPS617245A (ja) 1986-01-13

Similar Documents

Publication Publication Date Title
DE3583900D1 (de) Adrenergische verbindungen.
DE3481957D1 (de) Halbleiteranordnung.
DE3583302D1 (de) Halbleiteranordnung.
IT8520087A0 (it) Passante per collegamenti.
FI851114A0 (fi) Lagringsstabila, snabbt soederfallande farmaceutiska aktivaemnespresstycken.
FI850993A0 (fi) Utryckningsfordon, speciellt tankslaeckningsfordon foer flygfaelt.
FI851937L (fi) Utryckningsfordon, saerskilt brandbil.
DE3583521D1 (de) Antivirale verbindungen.
FI851505A0 (fi) Valsanordning, speciellt foer en kalander.
DE3672133D1 (de) Wirksame verbindungen.
DE3584852D1 (de) Antikonvulsive verbindungen.
DE3582653D1 (de) Halbleiteranordnung.
FI841948A0 (fi) Kanna, speciellt termoskanna.
DE3577009D1 (de) Photochrome verbindungen.
FI852087A0 (fi) Glidytsbelaeggning foer skida, speciellt terraengskida.
DE3586547D1 (de) Antibakterielle verbindungen.
FI851383L (fi) Polyfosfat innehaollande, flytande tvaettmedelskomposition foer tvaettinraettningar.
FI851935A0 (fi) Utryckningsfordon, saosom brandbil.
FI840878A (fi) Ventilations-/vaermevaexlarsystem foer djurskydd, saerskilt broilerhoenshus.
FI852088A0 (fi) Enhetliga, styva, fristaoende, gasgenomslaeppliga, laogtemperaturbundna sandkornsformar.
FI851743L (fi) Saekerhetsfoerslutningskork, saerskilt foer flaskor foer farmaceutiskt bruk.
DE3578424D1 (de) Quino-benzothiazin-antibakterielle verbindungen.
FI843996L (fi) Kluvet braensle-element foer kaernreaktor, isynnerhet foer kokvattenreaktor.
FI851206A0 (fi) Isoleringskaerl, saerskilt termoskanna.
DE3480714D1 (de) Kationische verbindungen.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee